Eli Lilly and Company (LLY) vs Novo Nordisk A/S (NVO)
LLY pairs fast growth and momentum with a premium multiple; NVO is cheaper with weaker estimates
Qanvo's scorecard gives LLY the lead on growth (100 vs 0), profitability and quality (83 vs 17), earnings momentum (67 vs 33), technical momentum (100 vs 0) and lower risk (75 vs 25), while NVO leads on valuation (100 vs 0). Financial resilience has no clear leader (50 each). LLY's revenue grew 45.51% against 5.72% for NVO, but it trades at a forward P/E of 29.11× against 12.20× for NVO. NVO offers a 4.41% dividend yield against 0.49%, yet analysts estimate next-year EPS growth of -1.59% for NVO against 42.63% for LLY. Margins are close, so the main differences lie in growth, cash conversion, price trend and what each price already assumes.
Business overview
Both companies are listed on the NYSE in the Healthcare sector, in the Drug Manufacturers - General industry, so their ratios are broadly comparable. Eli Lilly and Company (LLY) is a US-domiciled firm whose profile describes discovery, development, manufacture and sale of pharmaceuticals across diabetes, oncology, immunology and neuroscience. Novo Nordisk A/S (NVO) is Denmark-domiciled and describes two segments: Diabetes and Obesity Care, and Rare Disease, covering insulins, GLP-1 analogues, obesity management and haemophilia treatments. LLY is much larger by market value, at $1.26T (Mega tier) against $178.69B for NVO (Large tier). LLY reports 50,000 employees and NVO 68,794. For geography, only LLY has a breakdown in the facts: the United States was 66.71% of fiscal 2025 revenue and Europe 17.73%. No segment or regional split is available for NVO. One accounting caveat: LLY reports in USD and NVO in DKK, so amounts should not be compared directly, only rates and margins.
- LLY's market cap of $1.26T is far above NVO's $178.69B.
- Both sit in Drug Manufacturers - General, so valuation and margin ratios are comparable.
- LLY earned 66.71% of fiscal 2025 revenue in the United States; no equivalent split is available for NVO.
- LLY reports in USD and NVO in DKK, so only rates and margins compare.
Valuation
NVO is cheaper on every multiple in the facts, and Qanvo's scorecard names it the valuation leader (100 against 0 for LLY, a relative rank). Trailing P/E is 10.72× for NVO against 45.78× for LLY, and forward P/E (based on analyst estimates) is 12.20× against 29.11×. Price/sales is 3.64× against 14.60×, EV/EBITDA 7.39× against 29.21×, and free-cash-flow yield 3.83% against 1.56%. LLY's PEG is 0.68×; none is given for NVO. Against its own history, LLY's trailing P/E of 45.78× sits below its 5-year median of 55.13× and within a range of 33.2 to 137.95. No 5-year P/E history is available for NVO because its statements are in DKK while the shares trade in USD. Against sector peers, LLY's trailing P/E is at the 77th percentile (sector median 30.02×) and NVO's at the 6th percentile. The gap partly reflects fundamentals. LLY has far faster growth and higher quality scores, while NVO's analysts expect EPS to decline next year and it has weaker price momentum. A low multiple can signal doubt about future earnings as well as value.
- Trailing P/E is 10.72× for NVO against 45.78× for LLY.
- Forward P/E is 12.20× for NVO and 29.11× for LLY, against an industry median of 15.54×.
- Free-cash-flow yield is 3.83% for NVO against 1.56% for LLY.
- LLY's trailing P/E is below its own 5-year median of 55.13×; NVO has no comparable history.
Growth
LLY leads on growth by a wide margin (scorecard 100 against 0). Revenue growth over the last year was 45.51% for LLY against 5.72% for NVO, and last-quarter year-on-year growth was 38.61% against 5.63%. Over three years the gap narrows: revenue compound growth was 31.69% against 20.43%, and EPS compound growth was 51.73% against 23.52%. Latest-year EPS growth was 50.73% for LLY against 9.22% for NVO, though LLY's latest-quarter EPS growth slowed to 16.26% and NVO's turned negative at -15.78%. The history shows LLY's revenue rising each year from fiscal 2020 to 2025 and in six straight quarters, reaching $24.40B in Q3 FY2026. NVO's annual revenue also rose each year, but its quarterly revenue peaked at DKK 96.82B in Q1 FY2026 before falling to 79.19B in Q3. Analyst estimates point the same way: next-year EPS growth is 42.63% for LLY and -1.59% for NVO, with consensus EPS of 35.37 and 50.45 for LLY's next two fiscal years, against 3.38 and 3.33 for NVO.
- Revenue growth over the last year was 45.51% for LLY against 5.72% for NVO.
- Three-year EPS compound growth was 51.73% for LLY against 23.52% for NVO.
- Analysts estimate next-year EPS growth of 42.63% for LLY and -1.59% for NVO.
- LLY's revenue has risen for six straight quarters, while NVO's Q3 FY2026 revenue of DKK 79.19B is below its Q1 peak of DKK 96.82B.
Profitability, cash flow & financial health
Qanvo's profitability and quality scorecard puts LLY ahead, with a score of 83 against 17 for NVO. Margins are close, though. LLY's gross margin is 83.63% versus 80.79% for NVO, and its operating margin is 46.07% versus 42.39%. NVO has the higher net margin at 33.92% versus 31.90%, and the higher EBITDA margin at 52.81% versus 51.76%. The clearer gap is cash conversion: LLY's free cash flow margin is 22.74% against 13.94% for NVO. Free cash flow was $19.66B at LLY, with FCF growth of 117.95% year on year. NVO's FCF growth was -23.69%, and its capex of 12.06B (reported in DKK) absorbed much of its operating cash flow of 18.91B. Returns on capital are similar on ROIC, 37.07% for LLY and 36.52% for NVO, while LLY's ROE of 86.10% is well above NVO's 58.38%, partly reflecting LLY's thinner equity base. Over the past year LLY's gross margin changed by 0.61% and its operating margin by 1.65%. NVO's gross margin changed by -1.25% and its operating margin by 0.35%. LLY's growth is therefore turning into slightly better economics, while NVO's is flat to slightly weaker. On the balance sheet, Qanvo finds no clear leader. LLY's net debt/EBITDA is 1.00× and its debt/equity is 1.23×, versus 0.50× and 0.62× for NVO. LLY's current ratio is 1.39× against 0.84× for NVO. LLY discloses interest coverage of 33.81×; none is provided for NVO. Amounts differ in currency, so compare ratios, not sizes.
- LLY's FCF margin of 22.74% is well above NVO's 13.94%.
- LLY's operating margin of 46.07% is above NVO's 42.39%, but NVO's net margin of 33.92% is above LLY's 31.90%.
- NVO carries less leverage, with net debt/EBITDA of 0.50× versus 1.00× for LLY.
- LLY's current ratio of 1.39× is above NVO's 0.84×, so liquidity favours LLY while leverage favours NVO.
Shareholder returns & capital allocation
The two companies return capital in very different ways. NVO is the income-oriented name: its dividend yield is 4.41% with a payout ratio of 47.73%, versus 0.49% and 22.46% for LLY. NVO pays semi-annually, and its dividend per share over the past twelve months was 1.80 against 6.92 for LLY, which pays quarterly. Dividend growth over three years is stronger at NVO, 29.23%, than at LLY, 15.24%. LLY has raised its dividend for 11 years, versus 6 years for NVO. LLY's quarterly payment moved to 1.73 from 1.5 a year earlier. LLY's low yield is not a weakness, since it is reinvesting heavily for growth. On share count, both are modestly shrinking: shares changed -0.60% at LLY and -0.67% at NVO over one year. LLY's annual buybacks were $4.11B in fiscal 2025 versus dividends of $5.38B. NVO's buybacks fell to 1.39B from 20.18B in fiscal 2024 (reported in DKK), while dividends paid were 51.76B. That points to NVO shifting from repurchases toward dividends. The dividend payout of NVO sits against free cash flow that was lower than in 2024, 28.99B versus 69.66B, so the cash cover of that payout is a point to watch. Details on LLY's capex plans beyond the facts are not available.
- NVO's dividend yield of 4.41% is far above LLY's 0.49%.
- NVO's payout ratio of 47.73% is roughly double LLY's 22.46%.
- NVO's three-year dividend growth of 29.23% exceeds LLY's 15.24%, though LLY has 11 years of increases versus 6.
- Share counts fell at both, by 0.67% at NVO and 0.60% at LLY, so neither is diluting.
Earnings intelligence
Both companies beat EPS consensus in the last four reported quarters, but the market reacted differently. Lilly's EPS surprises were 31.00% (Oct 29, 2026), 30.94% (Aug 5), 22.67% (Apr 30) and 9.12% (Feb 4), with revenue surprises of 8.03%, 10.33%, 11.11% and 7.51%. Its price moves were 10.03%, 6.84%, 13.17% and 1.73%. Novo's EPS surprises were 20.62% (Nov 4, 2026), 21.27% (Aug 5), 10.20% (May 6) and 2.90% (Feb 3). Its revenue surprises were 8.63%, 8.51%, -1.38% and 1.96%, and its price moves were 0.41%, -4.55%, 3.36% and -18.34%. The facts also list Feb 4 and Aug 4 entries for Novo with different per-share figures and moves of -23.69% and -2.65%; they are not reconciled here. Lilly's beat streak is 8 quarters against 6 for Novo. Analyst EPS estimates were revised up over 30 days for both: 2.42% for Lilly and 4.10% for Novo. Novo's revision is larger, but Qanvo's earnings momentum scorecard leads with Lilly (67 vs 33), driven by the bigger surprise and longer streak. The next report for both is Feb 3, 2027, not confirmed. No guidance figures are in the facts. The latest report strengthened Lilly's relative case more clearly, given the 10.03% gain, while Novo's beat produced a 0.41% move.
- Lilly's last EPS surprise of 31.00% compares with 20.62% for Novo.
- Lilly has beaten EPS estimates 8 quarters in a row versus 6 for Novo.
- Novo's 30-day EPS revision of 4.10% is above Lilly's 2.42%.
- Both report next on Feb 3, 2027, with the date unconfirmed.
Technicals, relative performance & risk
Lilly leads on every price-return window. Price returns: 1 month 14.1% vs 5.9%; 3 months 19.6% vs -9.3%; 6 months 43.3% vs -8.1%; 1 year 38.5% vs -16.0%; 3 years 136.9% vs -60.7%; 5 years 442.0% vs -28.9% (Lilly vs Novo). Total returns with dividends keep the order, with Novo's 1-year total at -14.9% against 39.2% for Lilly, so Novo's 4.41% yield narrows the gap only slightly. Relative strength rating is 93 for Lilly and 44 for Novo. Lilly's RSI is 62.98 and the price sits 3.13% above its 20-day, 13.01% above its 50-day and 27.16% above its 200-day average, 4.05% below its 52-week high. Novo's RSI is 52.07; it is 1.25% above the 20-day and 2.01% above the 50-day but 5.35% below the 200-day, and 36.56% under its 52-week high. A death cross was recorded Sep 25, 2026. Risk is closer than the returns suggest: 30-day volatility is 35.36% for Lilly (HV30 listed as 35.36%) and 29.93% for Novo, but beta is 0.33 vs 0.86 and 1-year drawdown -23.31% vs -44.84%. Lilly's momentum conflicts with its valuation, since forward P/E is 29.11 against 12.20 for Novo.
- Lilly's 1-year price return of 38.5% compares with -16.0% for Novo.
- Lilly trades 27.16% above its 200-day average; Novo is 5.35% below.
- Novo's 1-year maximum drawdown of -44.84% is deeper than Lilly's -23.31%.
- Lilly's beta of 0.33 is below Novo's 0.86, though its 30-day volatility is higher.
Analyst & ownership sentiment
Analyst opinion favors LLY more clearly. Its rating score is 2 with a "Strong Buy" label across 15 analysts, and the latest consensus count shows 34 Buy, 9 Hold and 3 Sell. NVO's rating score is 3.5 with a "Sell" label across 21 analysts, though its separate consensus count reads 1 Strong Buy, 17 Buy, 4 Hold and 3 Sell. Those two NVO readings point in different directions, so the data does not give a single clean view. These are analysts' opinions, not facts about the future. On targets, LLY's mean is 1,453.18, only 2.66% above the price, with recent targets from firms such as BMO Capital at 1,650 and UBS at 1,625. NVO's recent targets in the facts are 40 from both BMO Capital (cut from 47) and Morgan Stanley, and no mean target is given. Estimate revisions over 30 days were 2.42% for LLY and 4.10% for NVO. Deutsche Bank downgraded NVO to Sell on Aug 27, 2026. Short interest is low for both: 0.81% of float for LLY and 0.86% for NVO. Insiders at LLY made 1 sale and no buys in 90 days (net -7.0M); NVO shows none. Institutions hold 88.93% of LLY, but filings lag by weeks, and NVO has no ownership data.
- LLY's consensus count of 34 Buy against 3 Sell compares with 17 Buy and 1 Strong Buy against 3 Sell for NVO.
- LLY's mean target of 1,453.18 implies only 2.66% upside, so much of the analyst optimism appears already in the price.
- NVO's 30-day EPS revision of 4.10% is above LLY's 2.42%, despite its weaker rating score of 3.5.
- Short float is similar at 0.81% for LLY and 0.86% for NVO.
Risks & catalysts
The main risks differ in kind. LLY's is valuation and expectations: forward P/E of 29.11× against NVO's 12.20×, and an industry median of 15.54×. It also relies on estimates, since next-year EPS growth of 42.63% is an analyst forecast. Debt is higher, with debt/equity of 1.23× versus 0.62× for NVO, though net debt/EBITDA is 1.00× versus 0.50×. Recent news cites a vendor data hack and drug pricing pressure in Washington. 66.71% of 2025 revenue came from the United States. NVO's risks are operational and price-based. Revenue growth is 5.72%, analysts expect EPS growth of -1.59% next year, free cash flow growth is -23.69%, and the current ratio is 0.84×. Its maximum 1-year drawdown is -44.84% against -23.31% for LLY, and it fell 23.69% on the Feb 4, 2026 earnings day. Its price is 36.56% below its 52-week high. Catalysts: both report on Feb 3, 2027 (not yet confirmed). LLY's latest quarterly dividend, 1.73, had an ex-date of Nov 13, 2026 and pays Dec 10, 2026. NVO's last ex-date was Aug 17, 2026, and no later date is in the facts.
- LLY's forward P/E of 29.11× is well above NVO's 12.20×, so it has less room for disappointment.
- NVO's max 1-year drawdown of -44.84% compares with -23.31% for LLY.
- LLY's debt/equity of 1.23× is roughly double NVO's 0.62×.
- Both companies' next earnings date is Feb 3, 2027, 78 days away and unconfirmed.
Analysis written November 18, 2026. AI-generated, for information only; not investment advice.